Pillar Biosciences’ FDA Approved Solid Tumor NGS Kit oncoReveal™ CDx Launched at Molecular Pathology Laboratory Network, Inc.
Natick, MA – July 30, 2024 – Pillar Biosciences, Inc., the leader in Decision Medicine™, has announced that Molecular Pathology Laboratory Network, Inc., (MPLN) is now the first national molecular reference laboratory to verify and launch oncoReveal™ CDx. The oncoReveal™ CDx pan-cancer solid tumor IVD kit has been FDA PMA approved for general tumor profiling for 22 clinically […]
Pillar Biosciences oncoReveal™ CDx pan-cancer solid tumor IVD now FDA approved for general tumor profiling on the Illumina MiSeq™Dx System
Company continues to execute on its global strategy to bring highly accurate and sensitive NGS cancer diagnostics to enable localized testing Natick, MA – April 23, 2024 Pillar Biosciences, Inc., the leader in Decision Medicine™, which develops and distributes next-generation sequencing (NGS) tests to localize testing and reduce time to treatment initiation and testing costs, today […]
Pillar Biosciences to Present at NYBIO | NYSE Life Science Company Showcase on December 14th
Natick, MA – December 7, 2023 – Pillar Biosciences is pleased to announce that Randy Pritchard, Chief Executive Officer, and Vincent Ricci, Chief Financial Officer, will be presenting at the NYBIO | NYSE Life Science Company Showcase on December 14th. This event, organized by NewYorkBIO in partnership with the New York Stock Exchange (NYSE), brings […]
Pillar Biosciences to Present New Scientific Data at Association for Molecular Pathology Annual Meeting
NATICK, Mass. – November 8, 2023 – (PR NEWSWIRE) – Pillar Biosciences, Inc., the leader in Decision Medicine™, today announced the company and scientific collaborators will collectively present eleven studies and two corporate workshops at the 2023 Association for Molecular Pathology (AMP) Annual Meeting from November 14 -18, 2023 in Salt Lake City, UT (Booth […]
Beckman Coulter Life Sciences and Pillar Biosciences Announce NGS Application Development Pipeline for the Biomek NGeniuS System
Assays Focus on Accelerating Cancer Research INDIANAPOLIS – November 6, 2023 – Beckman Coulter Life Sciences, a global leader in laboratory automation and innovation, continues to lead the way with next-generation sequencing (NGS) research solutions. Today the company announces a collaboration agreement with Pillar Biosciences, which develops and distributes IVD & RUO NGS testing solutions […]
Pillar Biosciences Launches oncoReveal Core LBx, an NGS Kit to Enable Localized Liquid Biopsy-Based Tumor Profiling
Research Use Only (RUO) NGS Kit will provide a simple, automatable, industry-leading liquid biopsy workflow NATICK, Mass. – September 19, 2023 – (PR NEWSWIRE) – Pillar Biosciences, Inc., the leader in Decision Medicine™, has announced the global launch of oncoReveal™ Core LBx, a research-use-only (RUO) next-generation sequencing (NGS) kit that will provide the foundation for laboratories […]
Illumina and Pillar Biosciences Partner to Improve Access to Personalized Cancer Treatment Options
SAN DIEGO, JULY 25, 2023 /PRNewswire/ — Illumina Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, and Pillar Biosciences Inc., the pioneers of Decision Medicine™, today announced a strategic partnership to make Pillar’s suite of oncology assays commercially available globally as part of the Illumina portfolio of oncology products. The agreement […]
Pillar Biosciences and KeyGene Enter into Licensing Agreement
NATICK, Mass. and WAGENINGEN, Netherlands, April 13, 2023 /PRNewswire/ — Pillar Biosciences, Inc., the leader in Decision Medicine™, which develops and distributes next-generation sequencing (NGS) tests to localize testing and reduce time to treatment initiation and testing costs, today announced a non-exclusive licensing agreement with Keygene N.V. related to their patent family entitled Combinatorial sequence barcodes for high throughput screeningfor use in Pillar […]
Pillar Biosciences Receives College of American Pathologists (CAP) Accreditation
NATICK, Mass.–(BUSINESS WIRE)–Pillar Biosciences, Inc., the leader in Decision Medicine™, which develops and distributes next-generation sequencing (NGS) tests to localize testing and reduce time to treatment initiation and testing costs, today announced their receipt of the College of American Pathologists (CAP) Accreditation for its CLIA certified reference lab. As one of the most rigorous laboratory certifications, the […]
Exquisitely Platinum-Sensitive Triple-Negative Breast Cancer, Time for BRCA Methylation Testing?
Tan JCO PRecis Oncol 2022 epigenetics germline